Price Alert

Y-mAbs Therapeutics Inc. (YMAB)

NASDAQ: YMAB · Real-Time Price · USD

8.52

0.01 (0.12%)

At close: Aug 15, 2025, 10:04 AM

0.12% (1D)

Bid	8.51
Market Cap	386.91M
Revenue (ttm)	88.66M
Net Income (ttm)	-28.23M
EPS (ttm)	-0.5
PE Ratio (ttm)	-17.03
Forward PE	-8.11
Analyst	Hold

Ask	8.52
Volume	158,921
Avg. Volume (20D)	670,201
Open	8.51
Previous Close	8.51
Day's Range	8.51 - 8.53
52-Week Range	3.55 - 16.11
Beta	0.56

About YMAB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol YMAB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for YMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Y-mAbs Therapeutics has released their quartely earnings on Aug 8, 2025:

Revenue of $19.52M exceeds estimates by $1.12M, with -14.36% YoY decline.

EPS of -0.07 exceeds estimates by 0.19, with 66.67% YoY growth.

Next Earnings Release

Y-mAbs Therapeutics Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+103.34%

Y-MAbs Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

8 months ago

-0.77%

Y-MAbs Therapeutics shares are trading higher after Brookline Capital initiated coverage on the stock with a Buy rating and announced a price target of $17.

News

6 days ago · zacks.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.

6 days ago · businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Clic...

6 days ago · fool.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The compa...

1 week ago · businesswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAb...

1 week ago · zacks.com

YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?

YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i...

1 week ago · https://thefly.com

Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley

Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per sha...

1 week ago · https://thefly.com

Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord

Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $26, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

1 week ago · https://thefly.com

Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer

Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in c...

1 week ago · https://thefly.com

Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline

Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

1 week ago · https://thefly.com

Y-mAbs Therapeutics downgraded to Hold from Buy at Truist

Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

Load More News